EULAR Updates ANCA-Associated Vasculitis Recommendations
A EULAR task force revised guidelines to reflect findings from randomized clinical trials that were published since the last update in 2016.
A EULAR task force revised guidelines to reflect findings from randomized clinical trials that were published since the last update in 2016.
Pentraxin-3 appears to reflect disease activity better than C-reactive protein.
An 86-year-old man with history of hypertension (HTN), chronic obstructive pulmonary disease (COPD), and allergic rhinitis presented with one-week history of nausea, vomiting, diarrhea, and abdominal pain. Home medications included albuterol inhaler, carvedilol, hydralazine, and losartan. In the emergency department, he was found to be hypertensive with a blood pressure (BP) of 194/70 mm Hg…
A population-based study of Swedish adults found that ANCA-associated vasculitis is more prevalent among men than women.
Use of the drug resulted in remission of severe pulmonary and cutaneous ANCA-associated vasculitis that resisted intensive conventional treatment.
Rituximab demonstrated superiority to azathioprine in a randomized trial.
Patients who experienced CMV viremia had significantly lower total protein, hemoglobin, and platelet and lymphocyte counts compared with those who did not.
Recent study provides insight into treatment outcomes over a relatively long time period.
Investigators conducted a subgroup analysis of patients with eGFR values of 20 mL/min/1.73 m2 or less in the phase 3 ADVOCATE trial.
In a proof of concept study, urinary T cells outperformed soluble biomarkers in discriminating disease activity.